ClinicalTrials.gg
Not yet recruitingNCT07782905Updated Aug 24, 2026

Talk2gether Program for Social Connection in Older Adults

An interventional study of Talk2gether program in Social Isolation or Loneliness, sponsored by The University of Texas Health Science Center, Houston. Not yet recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-08-24.

Sponsored by The University of Texas Health Science Center, Houston · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
65 Years and older
Sex
All
01

Study summary

The purpose of this study is to see if it is feasible to recruit and retain older adults in a, weekly phone call program delivered through the Harris County Precinct 2 Healthcare and Social Services Team and to see how participation in the program affect older adults' loneliness, social isolation, psychological well-being, and satisfaction, and what barriers or challenges arise during implementation

02

Conditions studied

  • Social Isolation or Loneliness

Keywords

  • Loneliness
  • social connectedness
  • psychological well-being
03

In context

Social Isolation

236 studies on the registry are indexed under Social Isolation; 61 are open to participants now.

This study's planned enrollment of 50 is below the median of 80 across 198 interventional studies indexed under Social Isolation.

Browse Social Isolation studies →

Lead sponsor

The University of Texas Health Science Center, Houston is the lead sponsor of 897 studies on the registry; 214 are open to participants now.

Of its 173 completed or terminated interventional studies of FDA-regulated products, 142 (82%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • able to provide
  • able to speaks English or Spanish
  • able to hear sufficiently using the telephone

Exclusion criteria

Exclusion Criteria:

  • Need for another person to consent on the participant's behalf
  • suspected or confirmed decision-making capacity impairments
  • uncontrolled psychiatric illnesses such as schizophrenia, paranoia, delusion, or delirium
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Talk2gether program

    Behavioral: Talk2gether program

Interventions

  • BehavioralTalk2gether program

    Participants will be paired with a trained team member. The team member will then initiate contact with the older adult(s) to begin 90 days of weekly social calls. These weekly social calls will be mostly unstructured, but supported by resource and conversation guides. At the end of 90 days, if the older adult wishes to continue to receive calls, that request will be accommodated

06

What researchers measure

Primary outcomes

  1. Program Feasibility as assessed by number of participants recruited

    Time frame: end of intervention (90 days after baseline)

  2. Program Feasibility as assessed by number of participants that adhered to the weekly calls

    Time frame: end of intervention (90 days after baseline)

  3. Feasibility as assessed by number of participants that completed the program

    Time frame: end of intervention (90 days after baseline)

  4. Feasibility as assessed by number of participants that encountered barriers or challenges as assessed by the Client Satisfaction Questionnaire (CSQ-8)

    This is an 8 item questionnaire and Items 2, 4, 5, and 8 are reverse scored. Total scores range from 8 to 32, with the higher number indicating greater satisfaction

    Time frame: end of intervention (90 days after baseline)

  5. Feasibility as assessed by number of participants that encountered barriers or challenges as reported on the Caller and Older Adult feedback form

    Time frame: end of intervention (90 days after baseline)

Secondary outcomes

  1. Change in social connectedness as assessed by the Lubben Social Network Scale-6

    This is a 6-item self-report measure assessing perceived social support and social network size from family and friends. Each item is scored from 0 to 5, and total scores range from 0 to 30. Higher scores indicate greater social connectedness and lower risk of social isolation

    Time frame: baseline, post-intervention (Day 90)

  2. Change in loneliness as assessed by the Patient-Reported Outcomes Measurement Information System (PROMIS) Social Isolation scale

    This is an 8 item scale. Each item is rated on a 5-point scale from 1(never) to 5 ( always). Raw scores range from 8 to 40 and are converted to PROMIS T-scores, with a mean of 50 and standard deviation of 10 in the reference population. Higher scores indicate greater perceived social isolation/loneliness.

    Time frame: Baseline, end of intervention (90 days)

  3. Change in depressive symptoms as assessed by the Patient Health Questionnaire-2

    This is a 2-item self-report measure . Each item is scored from 0 (not at all) to 3 (nearly every day). Total scores range from 0 to 6, with higher scores indicating greater depressive symptom burden.

    Time frame: Baseline, end of intervention (90 days)

  4. Change in signs of elder mistreatment as assessed by the Elder Mistreatment Screening and Response Tool (EM-SART).

    This is a 3 item questionnaire and each will be scored as either 1(yes) or 0(no) for a maximum score of 3. Higher scores or more endorsed concerns indicate a greater number of signs suggestive of elder mistreatment

    Time frame: Baseline, end of intervention (90 days)

  5. Change in sense of purpose using the 7-item Ryff Purpose in Life Scale.

    This is a 7 item questionnaire and each item is rated on a Likert-type scale, commonly from 1(strongly disagree) to 6( strongly agree). Negatively worded items are reverse scored, and item scores are summed to generate a total score. Total scores range from 7 to 42, with higher scores indicating a greater sense of purpose in life.

    Time frame: Baseline, end of intervention (90 days)

  6. Client satisfaction as assessed by the Client Satisfaction Questionnaire

    This is an 8 item questionnaire. Scores are summed across items once. Items 2, 4, 5, and 8 are reverse scored. Total scores range from 8 to 32, with the higher number indicating greater satisfaction

    Time frame: end of intervention (90 days)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Aug 2028, 24 months later.

Of 155 non-industry interventional studies with no phase under Social Isolation, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 24 months is above that.

Counting every sponsor, half of 156 studies reached it within 18 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2026
First posted
Aug 24, 2026
StartEst.
Aug 3, 2026
Primary completionEst.
Aug 3, 2028
CompletionEst.
Aug 3, 2028
Last update
Aug 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07782905
Responsible party
Jason Burnett (Associate Professor, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Aug 24, 2026
Start date
Aug 3, 2026 (estimated)
Primary completion
Aug 3, 2028 (estimated)
Completion
Aug 3, 2028 (estimated)
Last update
Aug 24, 2026

Study contacts

Jason Burnett, PhD
Contact
Jason.Burnett@uth.tmc.edu
(713) 873-4685
Jordan Broussard
Contact
Jordan.Broussard@uth.tmc.edu
713 500 0321
Jason Burnett, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion